Knocking on Wood

Posted by thumperguy @thumperguy, Jan 14, 2021

Allowing for the possibility that I'm out-of-my-tree and totally deluding myself, at the moment I'm awash in self-congratulation. I'm closing in on 16 months without a flare-up requiring antibiotics to tame. I've tweaked the twice daily treatment session so that I get it done in 23 minutes not counting clean-up time. Twenty-three minutes nebbing 7% saline, switching on the Thumper for only the final three minutes. By that time the saline is almost entirely gone. Somehow those 7 minutes render the whole experience less oneous. Don

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

@alleycatkate

@rvan.rvan I would hope too. I used to be very breathless. I have never gone on the big 3. My path has been just 7% saline, correcting my Gerd, excercising very regularly and eating well and I now breathe like a champ. (Oh, and I also take NAC for my lungs) I was originally haphazardly diagnosed by my GP as having COPD but later a pulmonologist found MAC and Bronchiectas.... Shortness of breath had been a problem for several years prior to diagnosis but cleared pretty shortly after addressing the Gerd and really taking care of my general health with a good diet and excercise. I am hopeful that you will get there. Sorry this is a winded response...but it is hard to say any one thing was responsible. Kate

Jump to this post

@alleycatkate Hello Kate could you please give more info on the NAC? brand, strength, and timing would be great. Thanks Bill

REPLY
@poodledoc

@alleycatkate Hello Kate could you please give more info on the NAC? brand, strength, and timing would be great. Thanks Bill

Jump to this post

yes, that would be great .. first timers here ..

REPLY
@poodledoc

@alleycatkate Hello Kate could you please give more info on the NAC? brand, strength, and timing would be great. Thanks Bill

Jump to this post

@poodledoc and @rvan ...Hi Bill and Ryan...well, another lenghly response from me. Seems my norm. 🙂
I googled MAC & NAC ...afraid of getting a cheezy recipe. Although none directly related to MAC, there are so many articles on NAC in relation to lung health, clearance, reduction of exacerbations etc. and mycobacterias...Following is one I found particularly interesting and I am posting an excerpt from the article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084440/ It is entitled N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its know anti-oxidative functions. I personally take NAC 600 mg 2x a day..made by NOW. Gee...if ever there was a go to supplement for our ills, I would think it would be NAC. Kate

N-acetyl-cysteine (NAC) is included in the World Health Organization’s list of essential medicines; a list that details the most relevant medications needed for a basic health system [1]. Acetyl-cysteine is a derivative of cysteine in which an acetyl group is attached to nitrogen. Due to its disulfide reducing activity, NAC is used as a mucolytic agent to promote expectoration [2]. NAC is commonly prescribed as an adjunct therapy in patients with a wide range of respiratory diseases characterized by formation of thick mucus, such as cystic fibrosis [2–4]. At high doses, NAC results in significantly improved small airway function and decreased exacerbation frequency in patients with stable chronic obstructive pulmonary disease (COPD) [3, 4]. NAC’s mucolytic activity is also the basis of its use in liquefying sputum samples for the microscopic detection of acid-fast bacilli (AFB) in suspected pulmonary tuberculosis (TB) patients [5]. Furthermore, in both experimental animal models and clinical studies, NAC displays a protective effect on acute liver injury induced by anti-TB drugs in acetaminophen-dependent or independent conditions [6–11]. In patients with type 2 diabetes, NAC holds promise in primary prevention of cardiovascular complications and systemic inflammation [12–14].

In addition to the above clinical applications, NAC has been employed as a potent anti-oxidant in several experimental models of infection and cancer in vitro and in vivo [15–20]. In these settings, NAC serves as a pro-drug to L-cysteine, which is a precursor to the biologic antioxidant glutathione. This anti-oxidant property of NAC is associated with strong anti-inflammatory effects, which have been suggested to inhibit the activation of nuclear factor-κB (NF-κB) with subsequent inhibition of cytokine synthesis [2, 21, 22]. In a mammalian model of Mycobacterium tuberculosis infection, NAC has been shown to diminish TB-driven lung pathology and inflammatory status, as well as to reduce mycobacterial infection loads in the lung [23]. These effects were attributed to the drug’s anti-oxidant properties and immune regulatory activities. Whether NAC limits M. tuberculosis infection in this situation through a direct microbicidal effect on M. tuberculosis was not addressed. Indeed, NAC has been shown to exhibit anti-microbial activity against a number of bacterial pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Helicobacter pylori, Klebsiella pneumoniae and Enterobacter cloacae [17, 24–26].

In this study, we demonstrate that NAC directly impairs the growth of several species of mycobacteria in vitro independent of its inhibitory effects on the host NADPH oxidase system. This anti-mycobacterial effect was also observed in an experimental model in vivo. Thus, NAC may limit M. tuberculosis infection and disease both through suppression of the host oxidative response and through direct antimicrobial activity. This dual host and pathogen directed function makes the drug an interesting candidate for use as adjunct therapy for tuberculosis.

REPLY
@alleycatkate

@poodledoc and @rvan ...Hi Bill and Ryan...well, another lenghly response from me. Seems my norm. 🙂
I googled MAC & NAC ...afraid of getting a cheezy recipe. Although none directly related to MAC, there are so many articles on NAC in relation to lung health, clearance, reduction of exacerbations etc. and mycobacterias...Following is one I found particularly interesting and I am posting an excerpt from the article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084440/ It is entitled N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its know anti-oxidative functions. I personally take NAC 600 mg 2x a day..made by NOW. Gee...if ever there was a go to supplement for our ills, I would think it would be NAC. Kate

N-acetyl-cysteine (NAC) is included in the World Health Organization’s list of essential medicines; a list that details the most relevant medications needed for a basic health system [1]. Acetyl-cysteine is a derivative of cysteine in which an acetyl group is attached to nitrogen. Due to its disulfide reducing activity, NAC is used as a mucolytic agent to promote expectoration [2]. NAC is commonly prescribed as an adjunct therapy in patients with a wide range of respiratory diseases characterized by formation of thick mucus, such as cystic fibrosis [2–4]. At high doses, NAC results in significantly improved small airway function and decreased exacerbation frequency in patients with stable chronic obstructive pulmonary disease (COPD) [3, 4]. NAC’s mucolytic activity is also the basis of its use in liquefying sputum samples for the microscopic detection of acid-fast bacilli (AFB) in suspected pulmonary tuberculosis (TB) patients [5]. Furthermore, in both experimental animal models and clinical studies, NAC displays a protective effect on acute liver injury induced by anti-TB drugs in acetaminophen-dependent or independent conditions [6–11]. In patients with type 2 diabetes, NAC holds promise in primary prevention of cardiovascular complications and systemic inflammation [12–14].

In addition to the above clinical applications, NAC has been employed as a potent anti-oxidant in several experimental models of infection and cancer in vitro and in vivo [15–20]. In these settings, NAC serves as a pro-drug to L-cysteine, which is a precursor to the biologic antioxidant glutathione. This anti-oxidant property of NAC is associated with strong anti-inflammatory effects, which have been suggested to inhibit the activation of nuclear factor-κB (NF-κB) with subsequent inhibition of cytokine synthesis [2, 21, 22]. In a mammalian model of Mycobacterium tuberculosis infection, NAC has been shown to diminish TB-driven lung pathology and inflammatory status, as well as to reduce mycobacterial infection loads in the lung [23]. These effects were attributed to the drug’s anti-oxidant properties and immune regulatory activities. Whether NAC limits M. tuberculosis infection in this situation through a direct microbicidal effect on M. tuberculosis was not addressed. Indeed, NAC has been shown to exhibit anti-microbial activity against a number of bacterial pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Helicobacter pylori, Klebsiella pneumoniae and Enterobacter cloacae [17, 24–26].

In this study, we demonstrate that NAC directly impairs the growth of several species of mycobacteria in vitro independent of its inhibitory effects on the host NADPH oxidase system. This anti-mycobacterial effect was also observed in an experimental model in vivo. Thus, NAC may limit M. tuberculosis infection and disease both through suppression of the host oxidative response and through direct antimicrobial activity. This dual host and pathogen directed function makes the drug an interesting candidate for use as adjunct therapy for tuberculosis.

Jump to this post

Thanks Kate 🙂 good read

REPLY
@alleycatkate

@goddard Hi Granny...There has been lots of discussion on this site about 3% vs 7% saline solution. If you can tolerate the 7, it seems to be superior. I am attaching a site that has a chart showing that the 7% is effective in killing MAC invitro. I think it speaks volumes to the efficacy of the higher solution vs the 3%. Please check chart 2 in the article. Best of luck to you. Kate
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850692/

Jump to this post

Thanks for forwarding citation. I agree this study says that 7% can be used therapeutically to kill MAC, but that 3% doesn't. . I will have to find the study my doc at UCLA referenced when my MAC was diagnosed in 2018, which said 3% was was as good--I think maybe the point of it (I cant remember) was whether 3% worked as well as mycolytic, thinning mucus (but not looking at whether saline was killing it). BTW, no doc has ever said anything about killing MAC with saline to me. After 15 years of totally dry cough, last spring I started having nagging productive cough instead of dry cough; in CT scan April 2020 some of mucus in little spots in middle lobe where I have bronchiectasis was gone, compared to some earlier scans. In 2018, I went to a doc who took the time to look at my CT scans from 2009-2018, and he said it waxed and waned over the years, would get better and worse. Im not sure if he meant the little spots of mucous were waxing and waning--

REPLY
@alleycatkate

@poodledoc and @rvan ...Hi Bill and Ryan...well, another lenghly response from me. Seems my norm. 🙂
I googled MAC & NAC ...afraid of getting a cheezy recipe. Although none directly related to MAC, there are so many articles on NAC in relation to lung health, clearance, reduction of exacerbations etc. and mycobacterias...Following is one I found particularly interesting and I am posting an excerpt from the article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084440/ It is entitled N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its know anti-oxidative functions. I personally take NAC 600 mg 2x a day..made by NOW. Gee...if ever there was a go to supplement for our ills, I would think it would be NAC. Kate

N-acetyl-cysteine (NAC) is included in the World Health Organization’s list of essential medicines; a list that details the most relevant medications needed for a basic health system [1]. Acetyl-cysteine is a derivative of cysteine in which an acetyl group is attached to nitrogen. Due to its disulfide reducing activity, NAC is used as a mucolytic agent to promote expectoration [2]. NAC is commonly prescribed as an adjunct therapy in patients with a wide range of respiratory diseases characterized by formation of thick mucus, such as cystic fibrosis [2–4]. At high doses, NAC results in significantly improved small airway function and decreased exacerbation frequency in patients with stable chronic obstructive pulmonary disease (COPD) [3, 4]. NAC’s mucolytic activity is also the basis of its use in liquefying sputum samples for the microscopic detection of acid-fast bacilli (AFB) in suspected pulmonary tuberculosis (TB) patients [5]. Furthermore, in both experimental animal models and clinical studies, NAC displays a protective effect on acute liver injury induced by anti-TB drugs in acetaminophen-dependent or independent conditions [6–11]. In patients with type 2 diabetes, NAC holds promise in primary prevention of cardiovascular complications and systemic inflammation [12–14].

In addition to the above clinical applications, NAC has been employed as a potent anti-oxidant in several experimental models of infection and cancer in vitro and in vivo [15–20]. In these settings, NAC serves as a pro-drug to L-cysteine, which is a precursor to the biologic antioxidant glutathione. This anti-oxidant property of NAC is associated with strong anti-inflammatory effects, which have been suggested to inhibit the activation of nuclear factor-κB (NF-κB) with subsequent inhibition of cytokine synthesis [2, 21, 22]. In a mammalian model of Mycobacterium tuberculosis infection, NAC has been shown to diminish TB-driven lung pathology and inflammatory status, as well as to reduce mycobacterial infection loads in the lung [23]. These effects were attributed to the drug’s anti-oxidant properties and immune regulatory activities. Whether NAC limits M. tuberculosis infection in this situation through a direct microbicidal effect on M. tuberculosis was not addressed. Indeed, NAC has been shown to exhibit anti-microbial activity against a number of bacterial pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Helicobacter pylori, Klebsiella pneumoniae and Enterobacter cloacae [17, 24–26].

In this study, we demonstrate that NAC directly impairs the growth of several species of mycobacteria in vitro independent of its inhibitory effects on the host NADPH oxidase system. This anti-mycobacterial effect was also observed in an experimental model in vivo. Thus, NAC may limit M. tuberculosis infection and disease both through suppression of the host oxidative response and through direct antimicrobial activity. This dual host and pathogen directed function makes the drug an interesting candidate for use as adjunct therapy for tuberculosis.

Jump to this post

@alleycatkate Thanks Kate. I have been using 600mg NOW brand NAC once daily, will increase to twice daily. That was a great article, here is another one I had saved on my computer, with similar conclusions.
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1042-x

REPLY

Is it your understanding that the GERD causes the bronchiectasis? which in turn sets you up for MAC by not allowing you to expel the MAC you've breathed in from normal air. Its my understanding that all sorts of people at any particular time might have some MAC bugs in their lungs because they are so common, but only those with MAC disease keep them in lungs, act as host to the bug. Is that your understanding? I had my most recent MAC doc tell me she thought I had GERD. But I dont have signs of it in my esophagus. I did not do the 24 hour test.

REPLY

what is difference between NAC and mucinex, and is NAC more effective as mucolytic?

REPLY
@goddard

what is difference between NAC and mucinex, and is NAC more effective as mucolytic?

Jump to this post

yes I am curious of this as well....

REPLY

I found this on the Memorial Sloan Kettering website on herbs and drugs-- it is a great site, as it references pretty much all studies on many OTC supplements, lists side effects, etc. NAC- "Results with NAC for chronic lung disease are mixed. Some studies indicate that it may reduce exacerbations (5) (44), inflammation (45), and help improve or maintain lung function (6) (38), but such benefits were not observed in other trials (7) (8) (37) (39). In addition, a meta-analysis suggests it is not the most effective mucolytic agent for chronic obstructive pulmonary disease (COPD) (46).
There has also been interest in NAC to improve psychiatric conditions, with preliminary benefit shown for addiction, substance abuse, and compulsive disorders (11) (12) (13) (14), but effects of adjunctive NAC on depressive symptoms are mixed (47) (48) (49)." (go to Mskcc.org site about herbs site for citations)

REPLY
Please sign in or register to post a reply.